AR078283A1 - Formulaciones de suspension oral de dibenzazepina carboxamidas - Google Patents

Formulaciones de suspension oral de dibenzazepina carboxamidas

Info

Publication number
AR078283A1
AR078283A1 ARP100103320A ARP100103320A AR078283A1 AR 078283 A1 AR078283 A1 AR 078283A1 AR P100103320 A ARP100103320 A AR P100103320A AR P100103320 A ARP100103320 A AR P100103320A AR 078283 A1 AR078283 A1 AR 078283A1
Authority
AR
Argentina
Prior art keywords
dibenzazepina
carboxamidas
oral suspension
suspension formulations
formulation
Prior art date
Application number
ARP100103320A
Other languages
English (en)
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of AR078283A1 publication Critical patent/AR078283A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Una formulacion de suspension oral que comprende acetato de eslicarbazepina y un vehículo líquido farmacéuticamente aceptable. Reivindicacion 10: La formulacion tal como se define en la reivindicacion 9, en donde el agente antimicrobiano comprende metilparabeno y/o propilparabeno.
ARP100103320A 2009-09-10 2010-09-10 Formulaciones de suspension oral de dibenzazepina carboxamidas AR078283A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24119509P 2009-09-10 2009-09-10

Publications (1)

Publication Number Publication Date
AR078283A1 true AR078283A1 (es) 2011-10-26

Family

ID=43037794

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103320A AR078283A1 (es) 2009-09-10 2010-09-10 Formulaciones de suspension oral de dibenzazepina carboxamidas

Country Status (13)

Country Link
US (2) US20130040939A1 (es)
EP (1) EP2475357A1 (es)
JP (1) JP2013504569A (es)
KR (1) KR20120094473A (es)
CN (1) CN102612359A (es)
AR (1) AR078283A1 (es)
AU (1) AU2010293105A1 (es)
BR (1) BR112012005254A2 (es)
CA (1) CA2773249A1 (es)
IN (1) IN2012DN02379A (es)
MX (1) MX2012002831A (es)
RU (1) RU2012113844A (es)
WO (1) WO2011031176A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
RU2012106827A (ru) 2009-07-27 2013-09-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Применение производных 5н-дибенз/в, f/азепин-5-карбоксамида для лечения фибромиалгии
RU2639120C2 (ru) 2011-08-26 2017-12-19 Биал-Портела Энд Ка, С.А. Лечение с использованием ацетата эсликарбазепина или эсликарбазепина
GB201306095D0 (en) * 2013-04-04 2013-05-22 Bial Portela & Ca Sa New treatments
JP6122815B2 (ja) * 2014-02-20 2017-04-26 ライオン株式会社 経口製剤及びその製造方法
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
WO2019058353A1 (en) * 2017-09-25 2019-03-28 Jubilant Generics Limited MODIFIED RELEASE SUSPENSION OF ESLICARBAZEPINE
US11318145B2 (en) 2018-09-25 2022-05-03 Jubilant Generics Limited Eslicarbazepine suspension
WO2019058354A1 (en) * 2017-09-25 2019-03-28 Jubilant Generics Limited SUSPENSION OF ESLICARBAZÉPINE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
JP3844491B2 (ja) * 1993-10-01 2006-11-15 シンテックス（ユー・エス・エイ）インコーポレイテッド ミコフェノール酸モフェチル高用量経口用懸濁剤
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
US6510799B2 (en) * 2001-07-02 2003-01-28 Magna Force, Inc. Apparatus, systems and methods for levitating and moving objects
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
CA2486553C (en) * 2002-06-17 2012-01-10 Taro Pharmaceuticals U.S.A., Inc. Ibuprofen suspension
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7118508B2 (en) * 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
WO2006018814A2 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Oral liquid suspensions of metaxalone
PT2380575E (pt) 2005-05-06 2015-06-17 Bial Portela & Ca Sa Acetato de eslicarbazepina e utilização
US20060252745A1 (en) * 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007007182A2 (en) * 2005-07-08 2007-01-18 Aurobindo Pharma Limited Solid and liquid dosage forms of an antiepileptic agent

Also Published As

Publication number Publication date
IN2012DN02379A (es) 2015-08-21
US20180256594A1 (en) 2018-09-13
JP2013504569A (ja) 2013-02-07
CN102612359A (zh) 2012-07-25
AU2010293105A1 (en) 2012-04-05
BR112012005254A2 (pt) 2016-03-15
MX2012002831A (es) 2012-05-08
RU2012113844A (ru) 2013-10-20
US20130040939A1 (en) 2013-02-14
WO2011031176A1 (en) 2011-03-17
KR20120094473A (ko) 2012-08-24
CA2773249A1 (en) 2011-03-17
EP2475357A1 (en) 2012-07-18
AU2010293105A8 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
AR078283A1 (es) Formulaciones de suspension oral de dibenzazepina carboxamidas
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
CR20130309A (es) Derivados de biciclo [3,2,1] octilamida y sus usos
WO2009072007A3 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
AR062000A1 (es) Formulaciones de modificador de respuesta inmune
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
MY154909A (en) Novel thiophene derivatives
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
MA34832B1 (fr) Compositions biodegradables d'administration de medicaments
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
RS52367B (en) GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
WO2013057570A3 (en) Acrylic polymer formulations
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
PE20140255A1 (es) Tableta dispersable en forma oral
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
AR082155A1 (es) Formulacion antiseptica y desinfectante que tiene contenido de yodo reducido
WO2009060952A1 (ja) 新規製剤
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
MX2013006493A (es) Composiciones para el cuidado bucal que comprende una quinona y un agente antimicrobiano adicional.
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid

Legal Events

Date Code Title Description
FB Suspension of granting procedure